Zobrazeno 1 - 10
of 470
pro vyhledávání: '"Shacham S"'
Autor:
Vergote, I.B., Lund, B., Peen, U., Umajuridze, Z., Mau-Sorensen, M., Kranich, A., Van Nieuwenhuysen, E., Haslund, C., Nottrup, T., Han, S.N., Concin, N., Unger, T.J., Chai, Y., Au, N., Rashal, T., Joshi, A., Crochiere, M., Landesman, Y., Shah, J., Shacham, S., Kauffman, M., Mirza, M.R.
Publikováno v:
In Gynecologic Oncology February 2020 156(2):308-314
Background: Despite a number of treatment options, patients with diffuse large B-cell lymphoma (DLBCL) whose disease has become refractory to treatment have a poor prognosis. Selinexor is a novel, oral drug that is approved to treat patients with rel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::c68321e34dc803adc3440696e2f723b6
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3076911
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3076911
Autor:
Shah, J., Shacham, S., Kauffman, M., Daniele, P., Tomaras, D., Tremblay, G., Casasnovas, R.O., Maerevoet, M., Zijlstra, J., Follows, G., Vermaat, J.S.P., Kalakonda, N., Goy, A.H., Choquet, S., Neste, E. van den, Hill, B.T., Thieblemont, C., Cavallo, F., Cruz, F. de la, Kuruvilla, J., Hamad, N., Bouabdallah, R., Jager, U., Caimi, P., Gurion, R., Warzocha, K., Bakhshi, S., Sancho, J.M., Schuster, M., Egyed, M., Offner, F., Vasilakopoulos, T.P., Samal, P., Nagy, A., Ku, M., Albendea, M.A.C.
Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10693::17cd4bbfd2cf83de9a819f46f1821002
https://hdl.handle.net/1887/3279611
https://hdl.handle.net/1887/3279611
Therapeutic regimens for previously treated multiple myeloma (MM) may not provide prolonged disease control and are often complicated by significant adverse events, including peripheral neuropathy. In patients with previously treated MM in the Phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::6d55190c74da78bac33deffe602fea08
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3076477
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3076477
Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::0e2f811591694d3135f36e92cda83222
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3077132
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3077132
In the phase 3 BOSTON study, patients with multiple myeloma (MM) after 1–3 prior regimens were randomized to once-weekly selinexor (an oral inhibitor of exportin 1 [XPO1]) plus bortezomib-dexamethasone (XVd) or twice-weekly bortezomib-dexamethasone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::6642cfc1f6edb7f253224e66314cecfb
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3101997
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3101997
Elderly and frail patients with multiple myeloma (MM) are more vulnerable to the toxicity of combination therapies, often resulting in treatment modifications and suboptimal outcomes. The phase 3 BOSTON study showed that once-weekly selinexor and bor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::79e7cdd57698b95815089a4a208b9b9c
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3102354
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3102354
Autor:
Shah, J, Shacham, S, Kauffman, M, Daniele, P, Tomaras, D, Tremblay, G, Casasnovas, RO, Maerevoet, M, Zijlstra, J, Follows, G, Vermaat, JSP, Kalakonda, N, Goy, AH, Choquet, S, Van den Neste, E, Hill, BT, Thieblemont, C, Cavallo, F, de la Cruz, F, Kuruvilla, J, Hamad, N, Bouabdallah, R, Jager, U, Caimi, P, Gurion, R, Warzocha, K, Bakhshi, S, Sancho, JM, Schuster, M, Egyed, M, Offner, F, Vasilakopoulos, TP, Samal, P, Nagy, A, Ku, M, Albendea, MAC
Publikováno v:
Future Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::bab2c32ec5c9f18330933aa07d83fa62
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4021
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4021
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kalakonda, N., Maerevoet, M., Cavallo, F., Follows, G., Goy, A., Vermaat, J.S.P., Casasnovas, O., Hamad, N., Zijlstra, J.M., Bakhshi, S., Bouabdallah, R., Choquet, S., Gurion, R., Hill, B., Jaeger, U., Sancho, J.M., Schuster, M., Thieblemont, C., Cruz, F. de la, Egyed, M., Mishra, S., Offner, F., Vassilakopoulos, T.P., Warzocha, K., McCarthy, D., Ma, X.W., Corona, K., Saint-Martin, J.R., Chang, H., Landesman, Y., Joshi, A., Wang, H.W., Shah, J., Shacham, S., Kauffman, M., Neste, E. van den, Canales, M.A.
Publikováno v:
Lancet Haematology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Lancet Haematology, 7(7), E509-E522. ELSEVIER SCI LTD
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Lancet Haematology, 7(7), E509-E522. ELSEVIER SCI LTD
Background Relapsed or refractory diffuse large B -cell lymphoma (DLBCL) is an aggressive cancer with a median overall survival of less than 6 months. We aimed to assess the response to single -agent selinexor, an oral selective inhibitor of nuclear
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::0b56206d52c8c303f1c0c046e72501ef
https://hdl.handle.net/1887/3185058
https://hdl.handle.net/1887/3185058